Solriamfetol: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
Create Solriamfetol page (Stahl-sourced detail with skepticism) |
MDElliottMD (talk | contribs) Tier 1 taxonomy consolidation: Category:Wake-Promoting Agents to Category:Eugeroics; Category:Norepinephrine Reuptake Inhibitors to Category:Norepinephrine Reuptake Inhibitors (NRIs) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
| brand = Sunosi | | brand = Sunosi | ||
| classes = Norepinephrine-dopamine reuptake inhibitor (NDRI), wake-promoting agent | | classes = Norepinephrine-dopamine reuptake inhibitor (NDRI), wake-promoting agent | ||
| mechanism = Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines | | mechanism = Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. | ||
| uses = Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) | | uses = Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) | ||
| starting_dose = Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. | | starting_dose = Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. | ||
| Line 14: | Line 14: | ||
| pregnancy = Limited data; pregnancy exposure registry available | | pregnancy = Limited data; pregnancy exposure registry available | ||
| legal = Rx, Schedule IV (US) | | legal = Rx, Schedule IV (US) | ||
| intro = '''Solriamfetol''' (brand name Sunosi) is a selective dopamine and norepinephrine reuptake inhibitor (NDRI) approved by the FDA in March 2019 for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. Unlike traditional stimulants (amphetamine, methylphenidate), solriamfetol does not significantly release monoamines from vesicles | | intro = '''Solriamfetol''' (brand name Sunosi) is a selective dopamine and norepinephrine reuptake inhibitor (NDRI) approved by the FDA in March 2019 for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. Unlike traditional stimulants (amphetamine, methylphenidate), solriamfetol does not significantly release monoamines from vesicles, it is purely a reuptake inhibitor, which may produce a smoother subjective effect with lower abuse potential. Lower scheduled (CIV) than the traditional stimulants (CII). Not indicated to treat underlying OSA (use with primary OSA therapy such as CPAP). | ||
| pharmacodynamics= Selective inhibitor of DAT and NET. Modest serotonin reuptake inhibition. Does not bind VMAT2 or cause significant monoamine release (contrast with amphetamine). | | pharmacodynamics= Selective inhibitor of DAT and NET. Modest serotonin reuptake inhibition. Does not bind VMAT2 or cause significant monoamine release (contrast with amphetamine). | ||
| effects = Headache, nausea, decreased appetite, anxiety, insomnia, palpitations, blood pressure / heart rate elevation. Avoid in patients with significant cardiovascular disease. | | effects = Headache, nausea, decreased appetite, anxiety, insomnia, palpitations, blood pressure / heart rate elevation. Avoid in patients with significant cardiovascular disease. | ||
| Line 20: | Line 20: | ||
}} | }} | ||
[[Category: | [[Category:Psychostimulants]] | ||
[[Category: | [[Category:Eugeroics]] | ||
[[Category:Dopamine Reuptake Inhibitors]] | [[Category:Dopamine Reuptake Inhibitors]] | ||
[[Category:Norepinephrine Reuptake Inhibitors]] | [[Category:Norepinephrine Reuptake Inhibitors (NRIs)]] | ||